Lundbeck Q3 2019 Financial Results

Eptinezumab - Powerful, Fast and Sustained action Eptinezumab promise * Rapid onset of prevention by Day 1 driven by IV formulation and 100% bioavailability, addressing unmet medical need * Strong response rate data from two phase III studies * Good tolerability profile similar to placebo at all dosages * Only prevention treatment available as an IV formulation * Quarterly administration: Potentially increased compliance for improved outcome * Alternative for patients uncomfortable with self injection * ~70% of ~2,000 target headache specialists/neurologists have capabilities to provide in-office IV therapies 20 20 Lundbeck

View entire presentation